Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

Same author

Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination.

Blood cancer journal·2012

Same author

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Same author

Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns.

Leukemia·2011

Same author

Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.

Leukemia·2011

Same author

The characterization of nuclear-DNA content, the proliferative activity and the immunohistochemical expression of gfap, vim, leu-7, s-100, p53 and cathepsin-d in human glioblastoma multiformes (hgbms) versus human gbm cell-lines grafted into the brains of nude-mice.

International journal of oncology·2011

Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026

Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026

Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026

Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026

Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026

Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

[Molecular abnormalities in lymphomas].

¹Université Paul-Sabatier,CHU de Toulouse-Purpan, Toulouse, France. georges.delsol@inserm.fr

Bulletin Du Cancer

|November 19, 2010

Summary

This summary is machine-generated.

Molecular abnormalities like mutations and translocations are key in diagnosing and classifying lymphomas. Understanding these genetic changes aids in developing targeted therapies for various lymphoma types.

More Related Videos

Chromosome Preparation From Cultured Cells

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Related Experiment Videos

Last Updated: Jun 6, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Chromosome Preparation From Cultured Cells

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Area of Science:

Hematology
Oncology
Molecular Biology

Context:

Lymphomas exhibit diverse molecular abnormalities crucial for diagnosis, prognosis, and classification.
These abnormalities include gene mutations, translocations, amplifications, and deletions, impacting tumor suppressor genes.
Techniques like cytogenetics, FISH, CGH array, and gene expression profiling detect these anomalies.

Purpose:

To review molecular abnormalities in common B, T, and NK cell lymphomas.
To highlight diagnostic and prognostic implications of these genetic alterations.
To discuss the role of molecular profiling in understanding lymphoma pathogenesis.

Summary:

Diffuse large B-cell lymphomas show distinct gene expression profiles (GCB vs. ABC).
Specific molecular alterations identified in follicular, MALT, mantle cell, and Burkitt lymphomas (e.g., BCL2, API2-MALT1, CCND1, c-Myc).
T and NK cell lymphomas, except ALK-positive anaplastic large cell lymphoma, have less recurrent molecular anomalies, though gene deregulation is noted.

Impact:

Molecular insights guide lymphoma classification (WHO) and therapeutic strategies.
Identification of ALK fusion protein in ALK-positive anaplastic large cell lymphoma offers a target for specific inhibitors.
Understanding infectious agent roles (EBV, HTLV1, H. pylori) in lymphomagenesis informs prevention and treatment.